One Capital Management LLC Has $3.11 Million Stake in Natera, Inc. $NTRA

One Capital Management LLC increased its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 38.1% in the 4th quarter, HoldingsChannel.com reports. The firm owned 13,559 shares of the medical research company’s stock after acquiring an additional 3,741 shares during the period. One Capital Management LLC’s holdings in Natera were worth $3,106,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in NTRA. Norges Bank acquired a new position in Natera during the fourth quarter worth $372,398,000. JPMorgan Chase & Co. lifted its stake in Natera by 9.4% in the third quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company’s stock valued at $1,871,914,000 after acquiring an additional 1,003,129 shares during the last quarter. Franklin Resources Inc. lifted its stake in Natera by 37.5% in the third quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock valued at $428,987,000 after acquiring an additional 727,366 shares during the last quarter. AQR Capital Management LLC lifted its stake in Natera by 39.0% in the third quarter. AQR Capital Management LLC now owns 2,400,065 shares of the medical research company’s stock valued at $386,338,000 after acquiring an additional 673,315 shares during the last quarter. Finally, Millennium Management LLC lifted its stake in Natera by 215.7% in the third quarter. Millennium Management LLC now owns 527,942 shares of the medical research company’s stock valued at $84,983,000 after acquiring an additional 360,733 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Stock Performance

NASDAQ NTRA opened at $213.05 on Wednesday. The firm has a 50-day moving average of $202.69 and a 200-day moving average of $215.84. The stock has a market cap of $30.51 billion, a PE ratio of -130.71 and a beta of 1.56. Natera, Inc. has a 52-week low of $131.81 and a 52-week high of $256.36.

Wall Street Analyst Weigh In

A number of brokerages have commented on NTRA. Evercore reiterated an “outperform” rating and issued a $270.00 price target on shares of Natera in a research note on Friday, May 8th. Wells Fargo & Company increased their price target on shares of Natera from $215.00 to $220.00 and gave the company an “equal weight” rating in a research note on Friday, May 8th. Wolfe Research started coverage on Natera in a research note on Tuesday. They issued an “outperform” rating and a $260.00 price target on the stock. Wall Street Zen downgraded Natera from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Finally, JPMorgan Chase & Co. raised their price target on Natera from $260.00 to $265.00 and gave the company an “overweight” rating in a report on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $256.81.

Insider Activity at Natera

In other news, CFO Michael Burkes Brophy sold 482 shares of the firm’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $210.49, for a total transaction of $101,456.18. Following the completion of the sale, the chief financial officer owned 57,496 shares in the company, valued at approximately $12,102,333.04. This trade represents a 0.83% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Fesko sold 1,438 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $202.84, for a total transaction of $291,683.92. Following the sale, the insider owned 185,782 shares of the company’s stock, valued at approximately $37,684,020.88. This represents a 0.77% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 34,406 shares of company stock worth $6,984,955. 5.05% of the stock is owned by corporate insiders.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.